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1. Introduction 
EGFR and HER2 family with signal pathway and carcinogenesis: The human epidermal 
growth factor receptors (HER-2) gene is localized to chromosome 17q and encodes a 
transmembrane tyrosine kinase receptor protein.  Numerous studies were done from basic 
mechanism of HER family for cell proliferation and oncogenesis, HER2 overexpression or 
amplification in various solid tumors to clinical treatment of breast cancer, gastro-
esophageal cancer by trastuzumab in many recent reviews [1-8]. 
HER2 belongs to a family including epidermal growth factor receptor (EGFR), HER2, HER3 
and HER4, which are a group of transmembrane glycoproteins, collectively named receptor 
tyrosine kinases (RTKs), whose cytoplasmic domains harbor an enzymatic activity, namely 
tyrosine-specific phosphorylation [9]. The family of epidermal growth factor molecules, 
which comprises different ligands sharing a 50–60 amino acid receptor-binding domain, 
bind with subtype RTKs. Each receptor consists of an extracellular ligand-binding domain, a 
transmembrane domain, and a tyrosine kinase portion [10]. Upon ligand binding, the 
otherwise inactive monomeric receptors form active homodimers or heterodimers, thereby 
leading to receptor phosphorylation and signaling via various biochemical pathways (Fig.1), 
such as the mitogen-activated protein kinase (MAPK), the phosphatidylinositol 3-kinase 
(PI3K), phospholipase C-γ, and transcription factors like the signal transducers and activators 
of transcription (STATs) or SMAD proteins [1]. These modules of cellular activation and the 
respective growth factors (GFs)s are co-opted in several phases of tumor progression. 
HER-2 gene amplification in breast cancer has been associated with increased cell 
proliferation, cell motility, tumor invasiveness, progressive regional and distant metastases, 
accelerated angiogenesis, and reduced apoptosis [11]. Overexpression of HER2 in human  
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Figure 1. Signal transduction pathways instigated by HER2, co-receptors and EGF-like growth factors. 
Heterodimers of HER2/ErbB-2 and either EGFR/ErbB-1 or the kinase-defective ErbB-3/HER3 (note the 
letter X that symbolizes a defective cytoplasm-facing kinase domain) are shown, along with the growth 
factor ligands they bind. All ligands share an epidermal growth factor (EGF) motif of 50–60 amino 
acids. They include, in addition to EGF, epiregulin (EPG), transforming growth factor alpha (TGF-
alpha), heparin-binding epidermal growth factor-like factor (HB-EGF), amphiregulin (AR), epiregulin 
(EPR) and betacellulin. Another group includes four classes of neuregulins (NRGs). Note that HER2 is 
unable to bind a ligand. Nevertheless, HER2 takes part in signaling via its own constitutive 
phosphorylation, as well as by trans-activation of its heterodimerization partners. Tyrosine 
phsphorylated receptors are coupled to several biochemical cascades, including the phosphoinositide-3-
kinase (PI3K) pathway and the extracellular signal-regulated kinase (ERK), which belongs to the MAPK 
family. Activation of ERK/MAPK is mediated via the RAS-RAF-MEK pathway and leads to cellular 
proliferation via the activation of a number of nuclear targets, including the AP1 (FOS and JUN) 
complex, MYC, which regulates cell cycle progression, and ELK1, a member of the ETS family of 
transcription factors. SHC and GRB2 are adaptor proteins sharing the ability to bind each other, as well 
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as tyrosine phosphorylated receptors. The EGFR/HER2 heterodimer also couples to phospholipase C 
(PLC) and the downstream protein kinase C. On the other hand, ErbB-3/HER3-containing heterodimers 
strongly activate another kinase, AKT, via a lipid kinase, PI3K, leading to activation of mTOR 
(mechanistic target of rapamycin). Activation of AKT blocks signaling via BAD, a BH3-only protein, 
which contributes to tissue homeostasis by regulating initiation of apoptosis. Activation of AKT inhibits 
FKHR and the cyclin-dependent kinase inhibitor p27KIP. The forkhead box O1 (FKHR, FOXO1) 
transcription factor is a member of the FOXO family of transcription factors, involved in tumor 
suppression and cell death. (From Emde A, et al. Crit Rev Oncol/Hematol (2010), 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002, Permitted by Elsevier Limited). 
mammary epithelial cells induces proliferative advantage, transformed characteristics, 
tumorigenic growth, and induces proliferative and anti-apoptotic changes that mimic early 
stages of epithelial cell transformation [12]. HER2 amplification is also seen in early in situ 
ductal carcinomas without any evidence of invasive disease [13, 14]. HER2 status is 
maintained during progression to invasive disease, nodal metastasis and distant metastasis 
[14, 15]. HER2 overexpression has been shown to activate multiple signaling complexes, 
which results in a striking dysregulation of the global transcriptome [1].  
Clinical treatment targeting on HER2 receptor:  It took a long journey to develop 
monoantibody to target HER2. Murine origin of mAb to HER2 limits their clinical 
application since immunoglobulin molecules are immunogenic. When injected into humans, 
it shortens their half-lives in circulation. Winter and colleagues (1988) generated a mouse–
human chimeric antibody [16]. Later transgenic mice whose immunoglobulin loc have been 
genetically inactive, was used to produce the first fully human antibody, Panitumumab, an 
antibody to EGFR. Then, trastuzumab which carry all human immunoglobulin genes, a 
monoclonal antibody to HER2, was approved for clinical use in lymphoma and in breast 
cancer [17]. So far, only two drugs that target HER2, Trastuzumab and a kinase inhibitor 
called Lapatinib/Tykerb, are approved for clinical application in breast cancer, but several 
novel drugs are in development (see figure 2). 
Trastuzumab, monoclone antibody on HER2: Trastuzumab, a monoclonal antibody that 
targets HER2, induces antibody-dependent cellular cytotoxicity, inhibits HER2-mediated 
signaling and prevents cleavage of the extracellular domain of HER2 [12]. Based on multi-
centers and countries clinical trial for HER2 positive breast cancer, [18,19,20] trastuzumab 
was significantly improve the prognosis of breast cancer. Therefore, it was initially 
approved for treatment of patients with HER2 overexpressing metastatic breast cancer. 
Because Trastuzumab also enhances the efficacy of adjuvant chemotherapy in operable or 
locally advanced HER2-positive tumors [21], the antibody currently represents the standard 
of care for patients with early or advanced stages of HER2-overexpressing breast cancer.  
Since breast cancer showed better prognosis with trastuzumab treatment for HER2 positive 
breast cancer patients and similar HER2 positive cancers were identified in gastric and 
gastro-esophageal cancer, clinical trial ToGA was performed in gastric carcinoma. ToGA 
(Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomized 
controlled trial undertaken in 122 centers in 24 countries [22]. Clinical trial ToGA used 
trastuzumab combined with standard chemotherapy for HER2 positive gastric cancer and 
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gastro-esophageal junction cancer which demonstrated a significant improvement of gastric 
cancer survival. Now, trastuzumab is approved for treatment of gastric cancer in European, 
United States, Japan and other multiple countries.  
 
Figure 2. Clinically approved and experimental therapeutic strategies targeting ErbB-2/HER2 in 
carcinomas. Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain 
of HER2, is approved for the treatment of HER2-overexpressing breast cancer. The antibody recruits 
immune effector mechanisms and can induce apoptosis, block angiogenesis and inhibit tumor cell 
proliferation. Similarly, Pertuzumab is able to prevent heterodimerization of HER2 with other family 
members. Unlike the ultimate specificity of Trastuzumab and Pertuzumab to HER2, tyrosine kinase 
inhibitors like the reversible inhibitor Lapatinib (approved for treatment of breast cancer) and the 
irreversible inhibitor Neratinib variably inhibit a broad range of tyrosine kinases. The drug has 
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completed phase II clinical trials. HSP90 is a molecular chaperone required for proper folding of protein 
kinases like HER2. Hence, HSP90 inhibitors, such as 17-AAG, which block the ATP/ADP binding 
pocket of HSP90 and target HER2 for proteasomal degradation are in clinical trials. A naturally 
occurring truncated form of HER2, p95-HER2, has been implicated as a mechanism conferring 
resistance to Trastuzumab. Its formation is mediated by processing of the membrane bound HER2 by 
matrix metalloproteinases (MMPs) of the ADAM (a disintegrin and metalloproteinase) family. INCB3619 
and INCB7839 are potent inhibitors of ADAM10 and ADAM17. ADAM10 is the principle sheddase for 
different molecules associated with tumor cell proliferation, whereas ADAM17 is the main sheddase for 
the EGFR ligands TGF-alpha, AR, NRGs, and HB-EGF. These similar inhibitors may effectively block 
truncation of HER2 and onset of patient resistance to Trastuzumab, but clinical testing has not been 
completed. (From Emde A, et al. Crit Rev Oncol/Hematol (2010), 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002, Permitted by Elsevier Limited). 
The clinical efficacy of Trastuzumab likely entails a combination of immunological and non-
immunological mechanisms [1]. The ability of Trastuzumab to elicit antibody-dependent 
cellular cytotoxicity critically influences the efficacy of Trastuzumab-based therapies. Non-
immunological mechanisms of Trastuzumab action include the inhibition of HER2 
activation and downstream signaling. Alternatively, Trastuzumab may act by removing 
HER2 from the cell surface. Because it binds to an epitope near the cleavage site of HER2's 
extracellular domain, Trastuzumab inhibits HER2 activation by metalloproteinase-mediated 
shedding of the extracellular domain. The resulting interference with HER2-mediated 
downstream signaling processes shuts down cell proliferation, angiogenesis, invasive 
growth, resistance to apoptosis, and DNA repair, thus sensitizing tumor cells to 
conventional therapeutic modalities such as chemotherapy, endocrine treatment and 
radiotherapy. 
Lapatinib, small molecule kinase inhibitor: Lapatinib, binding either reversibly or 
irreversibly to the nucleotide-binding cleft of their target kinases, is a highly specific, 
reversible inhibitor that blocks the catalytic action of both HER2 and EGFR23. Experiments in 
vitro and xenograft models, established the ability of Lapatinib to inhibit both the intact 
form of HER2 and the truncated intracellular form (p95-HER2), which is not recognized by 
Trastuzumab. 
Similar to Trastuzumab, Lapatinib combined with chemotherapy was found to be better 
effect than capecitabine alone in HER2-positive women with advanced breast cancer that 
progressed after treatment with regimens that included Trastuzumab, an anthracycline and 
a taxane [24]. In addition, Lapatinib demonstrated clinical activity and was well tolerated as 
first-line monotherapy in HER2-amplified, locally advanced or metastatic breast cancer [25, 
26]. Recently, laptinib showed a synergistic effect with trastuzumab in vitro and in vivo to 
inhibit HER2 amplified human gastric cancer cells and animal model [23]. Clinical phase II 
trial of lapatinib as first line therapy in patients with advanced or metastatic cancer showed 
well tolerated, which will be another potential drug to target HER2 receptors. 
Lapatinib response correlated with EGFR and HER2 expression levels in patients’ tumors, 
and associated with increased pre-treatment expression of phosphorylated-HER2 (p-
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HER2)[27]. Lapatinib is able to induce apoptosis of Trastuzumab-resistant breast cancer cells 
via alteration of IGF-1 signaling, [28, 29] and also block NRG-induced p95-HER2/HER3 
heterodimers formation [30]. 
2. HER2 in gastric adenocarcinoma 
Gastric cancer is the fourth most common cancer worldwide and the second most common 
cause of cancer-related death in the world [31, 32]. The incidence of gastric cancer varies 
substantially worldwide, with the highest rates (>20 per 100,000) occurring in Japan, China, 
Eastern Europe, and South America, but the lowest rates (<10 per 100,000) finding in North 
America, southern Asia, North and East Africa, Australia, and New Zealand. In addition, it 
is more common in men than in women (10.9 vas 5.5 per 100,000). Although the survival of 
gastric cancer is improved in recently years in Western countries the 5 year survival is still 
around 5-20%. The multimodality treatments including surgery and neoadjuvent 
chemotherapy have a limited effect on the overall survival. In breast cancer, HER2 
overexpression and amplification were reported around 25% and associate with poorer 
prognosis [2]. Trastuzumab treatment of HER2 positive breast cancer patient improved 
survival. HER2 overexpression and amplification were reported in gastric and gastro-
esophageal junction (GEJ) tumors from 6-43%. In addition, trastuzumab were found to 
inhibit tumor growth in gastric carcinoma cell lines, animal model and xenograft models 
[33-35]. Recently international large scale phase III clinical trial called ToGA showed that 
trastuzumab added to standard chemotherapy significantly improved the response rate, 
median progression-free survival, and overall survival of gastric adenocarcinoma[22]. 
Trastuzumab combined with standard chemical therapy (such as capecitabine or 5-
fluorouracil and cisplatin) now is approved by European Medicines Agency, United States 
and Japan etc. for the treatment of patients with HER2 overexpression or amplification. 
Thus clinical tests for HER2 overexpression and amplification in gastric adenocarcinoma 
patients become a key to recruit eligible patients for clinical treatment and evaluation of 
treatment effect. 
IHC studies on HER2 overexpression: HER 2 overexpression was reported from 7-34% by 
many studies [3]. For clinical trial and treatment, it is very important to develop a standard 
HER2 test to recruit eligible patients for trastuzumab treatment. Before clinical trial ToGA, 
Hofmann and colleagues (2008)[36] first set up an IHC criteria based on HER2 IHC test on 
168 gastric and GEJ resection patients (see Table 2).  Based on the standard HER2 test on the 
breast cancer, they further proposed that strong incompletely membranous stain with 
basolateral “U” shape in gastric cancer was positive for HER2 overexpression. In addition, 
the HER2 expression showed higher heterogeneity about 4.8% in gastric samples than about 
1.4% in breast cancer. They modified breast criteria in several points including incomplete 
membranous stain pattern and percentage of cells (≥ 10% cut off), which improved the 
concordance level between IHC and FISH tests to 93.5%. For ToGA clinical trial, Bang et al 
[22] reported that HER2 positive rate was a 22.1%. In addition, they found that HER2- 
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Gastric Cancer  Breast Cancer Score/classification 
IHC score criteria
No reactivity or membranous 
reactivity in <10% of cells; 
Biopsy specimens < 5 Cells 
No reactivity or membranous 
reactivity in <10% of cells 
0/negative 
Faint/barely perceptible 
membranous reactivity in ≥10% 
of cells;  biopsy specimens≥5 
Cells 
Faint membranous reactivity in 
>10% of cells; 
1+/negative 
Weak to moderate complete or 
basolateral membranous activity 
in ≥10% of tumor cells; biopsy 
specimens≥5 Cells 
Weak to moderate complete 
membrane staining in >10% of 
tumor cells  
 
2+/equivocal 
Moderate to strong complete or 
basal/lateral membranous 
activity  in ≥10% of resection 
tumor cells; biopsy specimens≥5 
Cells 
Strong complete membrane 
staining in >10% of tumor cells 
3+/positive 
FISH HER2/CEP 17  
≥ 2 At least 20 evaluable, non-
overlapping cells in the invasive 
component 
> 2.2 At least 20 evaluable, non-
overlapping cells in the invasive 
component
Amplification 
 1.8-2.2 Equivocal 
<2 At least 20 evaluable, non-
overlapping cells in the invasive 
component 
<1.8 At least 20 evaluable, non-
overlapping cells in the invasive 
component
negative 
Table 1. Consensus panel recommendations on HER2 scoring for gastric cancer 
positive rate were higher in GEJ cancer than in gastric cancer (33% vs 21%) and in intestinal 
than diffuse or mixed cancer (32.2% vs 6.1% vs 20.4%). The concordance between IHC and 
FISH was 87.5%. Ruschoff and colleaguesl37, 38(2010, 2012) further validate the HER2 test 
procedure to determine whether pathologists from different sits  were able to reproduce the 
method of gastric cancer HER2 status evaluation as it was used by Ruschoff within the 
ToGA study. They validated the HER2 status testing procedure in terms of inter-laboratory 
and inter-observe consensus for IHC scoring a series of 547 gastric cancer tissue samples on 
a tissue microarray.  They published a practical approach of HER2 test in gastric carcinoma. 
Based on multiple laboratories and 8 pathologists HER2 test results, they further confirmed 
the HER2 positive rate of 22.8% which is close to 22.1% from Hoffman’s score system. In 
addition, they compared Daco (HecepTest) and Ventana (Pathway HER2 antibody, 4B5).  
They found that HercepTest had a higher inter-laboratory discordance than 4B5.  
Furthermore, Ruschoff and a group of international pathologist reviewed previous HER2 
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studies; they built up new detailed criteria for gastric and gastro-esophageal HER2 tests (see 
Table 3; Ruschoff 2012). In their practical procedure for gastric cancer HER2 test, the surgical 
specimen cutoff is complete, basolateral, or lateral membranous reactivity in ≥10% of cells; 
the biopsy specimen cutoff is complete, basolateral, or lateral membranous reactivity in ≥5 
clustered cells; the borderline cutoff is immunohistochemistry 1+/immunohistochemistry 2+ 
or focal staining in <10% cells which recommend for FISH or SISH tests. This new score 
system further improved Hoffmann’s score system, but it still need further proved in future 
HER2 tests, especially the results mostly based on European laboratories. The large scale 
HER2 studies in Asia are need to build up an optimal HER2 test system in gastric cancer 




 Representative surgical samples or an adequate number of viable biopsy specimens (ideally 
six to eight) are required 
 If few biopsies are available, all viable specimens should be tested 
 Immunohistochemistry should be the initial HER2 testing methodology for gastric cancer 
and bright-field methodologies are preferred wherever possible 
HER2-positive per European Medicines Agency license: immunohistochemistry 3+ or 
immunohistochemistry 2+/fluorescence in situ hybridization-positive or 
immunohistochemistry 2+/silver in situ hybridization-positive 
Borderline immunohistochemistry 1+/immunohistochemistry 2+ cases and samples with 
focal and intense membranous reactivity in <10% cells may also be retested with 
fluorescence in situ hybridization or silver in situ hybridization (scores for both assays 
should be indicated separately on the report) 
 Validated immunohistochemistry HER2 assays should be used 
Scoring recommendations 
 Due to the tumor heterogeneity (focal areas of positivity) and incomplete membrane staining 
commonly seen in gastric cancer, the gastric cancer-specific scoring criteria should be 
adhered to: 
 Surgical specimen cutoff: complete, basolateral, or lateral membranous reactivity in 
≥10% of cells 
 Biopsy specimen cutoff: complete, basolateral, or lateral membranous reactivity in 
≥5 clustered cells 
 The ‘magnification rule’ should be used in conjunction with the scoring criteria 
 Borderline cases (immunohistochemistry 1+/immunohistochemistry 2+ or focal staining in 
<10% cells) that score fluorescence in situ hybridization-positive or silver in situ 
hybridization-positive may be considered HER2-positive (scores for both assays should be 
indicated separately on the report) 
b. In situ hybridization 
Testing recommendations 
  Tumor samples classified as immunohistochemistry 2+ should be retested by fluorescence 
in situ hybridization or silver in situ hybridization to assess HER2 status 
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  Silver in situ hybridization is a more suitable methodology than fluorescence in situ 
hybridization for assessing HER2 status in gastric tumor samples as it is a bright-field 
methodology and thus allows for rapid identification of HER2-positive tumor foci within a 
heterogeneous sample 
Validated in situ hybridization HER2 assays should be used 
Scoring recommendations 
 The definition of fluorescence in situ hybridization or silver in situ hybridization positivity in 
gastric or gastro–esophageal junction cancer is a HER2:chromosome 17 ratio of ≥2.0 
 The entire case should be screened for amplified regions (particularly important for 
fluorescence in situ hybridization samples where a bright-field image is not available) 
 At least 20 evaluable, non-overlapping cells in the invasive component should be counted 
initially 
 In borderline amplification cases, ~20 additional cells should be recounted or scoring should 
be performed in an alternative area of tissue 
The overall HER2 gene count is important: 
 >6 HER2 gene copies using single probe: considered positive 
 Four to six HER2 gene copies: dual probe test advised and the ratio should be 
recalculated by counting an additional 20 cells 
Ensuring quality and timely HER2 testing results 
 The use of validated immunohistochemistry and in situ hybridization tests is strongly 
recommended and appropriate controls should be included in each run 
 Turnaround time from initial diagnosis to reporting of results should ideally not exceed 5 
working days and a multidisciplinary approach is required 
 Centralized testing is recommended wherever possible and all laboratories should 
participate in validated quality assurance programs 
Table 2. Human epidermal growth factor receptor 2 (HER2) testing recommendations in gastric cancer, 
(a) immunohistochemistry and (b) in situ hybridization (From Ruschoff J, Hanna W, Bilous M, et al. 
HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012) 
 
HER2 immunohistochemistry features Score 
No reactivity or very faint membranous stain in <10% of cells; 
biopsy specimens<5 Cells 
0 
Faint membranous stain in >10% of cells; biopsy specimens≥5 Cells 1+ 
Weak to moderate complete or baso/lateral membranous stain in >10% of tumor 
cells; biopsy specimens≥5 Cells 
2+/positive 
Strong complete or basal/lateral membranous stain in >10% of tumor cells; 
biopsy specimens≥5 Cells 
3+/positive 
HER2 FISH/chromogenic in situ hybridization test  
Ratio of average HER2/CEP17 ≥2.0 Positive 
Ratio of average HER2/CEP17 <2.0 Negative 
Table 3. Modified score criteria of HER2 immunohistochemical stain and FISH/chromogenic in situ 
hybridization for esophageal adenocarcinoma  
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Recently, in Asia, several IHC HER2 tests focused on comparing the HER2 antibodies from 
various companies. Cho and colleagues [39] used four different HER2 antibodies compared 
to standard FISH test. They found the various positive rates with HercepTest (14%), A0485 
(16%), 4B5 (14%), and CB11 (9%). The sensitivity and specificity of IHC compared to FISH 
was 78.9%/96% for HercepTest, 86.5%/94.4% for A0485, 76.3%/95.6% for 4B5 and 
60.5%/98.4% for CB11. Compare to FISH, there was no significantly differences in the 
sensitivity and specificity among the four IHC tests. However, CB11 had a highest 
specificity (98%), but a lowest sensitivity (61%). Park et al [39] (2012) compared HercepTest 
with 4B5, only 41 cases showed discrepancies, yielding a 96.1% concordance rate. However, 
HER2 positive rate with both methods are very low: HecepTEST, 5.9% and 4B5, 6.4%.   
In addition, the standard breast HER2 test was compared with modified gastric carcinoma 
HER2 test (Table2). Sever studies used breast cancer score rule [40-42]. Barros-Silva et al. [40] 
found 3.9% as IHC2+ and 5.4% as IHC3+ from resection 463 gastric adenocarcinomas using 
the breast cancer scoring rules. Using breast cancer scoring, Park et al. (2012)[41] found that 
HER2 positive rate are very low with two antibodies: HecepTEST, 5.9% and 4B5, 6.4%. The 
similar result also was presented in TMA data which were classified as IHC2+ (1.6%) or 
IHC3+ (3.2%) if breast cancer scoring was applied[42]. As the same group also tested gastric 
cancer TMAs using gastric cancer specific scoring [36]the corresponding rates were 4% 
IHC2+ and 13% for IHC3+, demonstrating an about fourfold increase of HER2 positivity 
rate[42]. Therefore, Rushcoff concluded that it is supposed that application of breast cancer 
scoring to gastric cancer may produce an up to 50% false-negative rate if IHC is used as the 
primary test platform as favored by EMEA[37]. 
FISH, CISH and SISH studies on HER2 amplification: HER2 amplification was first 
reported  in gastric cancer in 198643. Since then, HER2 amplification in gastric cancer was 
extensively studied (see Table 3). Kimura  et al. 44 first set criteria of FISH test as 
HER2/CEP17 ≥ 2.0 which is modified from breast standard HER2 FISH test with 83% of 
concordance between IHC 2+ and 3+ samples. Hoffman et al.36 proved that these FISH 
criteria for gastric cancer showed a higher concordance (93%) between HER2 amplification 
and overexpression in gastric cancer. Ruschoff  et al. 38, 45  (2010, 2012) further validate the 
HER2 test procedure to determine whether pathologists from different sits  were able to 
reproduce the method of gastric cancer HER2 status evaluation as it was used by Ruschoff 
within the ToGA study. HER2 amplification was determined by FISH assays, using either 
HER2 FISH pharmDX™ (Dako Denmark A/S) or PathVysion® (Abbott Laboratories, Des 
Plaines, IL, USA). Automated brightfield dual-color silver in situ hybridization (SISH) assay 
(BDISH; Inform™, Ventana Medical Systems SA) was used to determine gene amplification 
at three of the participating sites. Based on their experience and previous studies, a new 
practical procedure for HER2 FISH, CISH or SISH tests were established. The positivity of 
HER2 FISH, CISH or SISH tests in gastric or gastro-esophageal junction cancer is a 
HER2/Chromosome 17 ratio ≥ 2.0 and > 6 HER2 gene copies using single probe.  At least 20 
evaluable, non-overlapping cells in the invasive component should be counted initially. If 
the results are borderline (four to six HER2 gene copies or HER2/Chromosome 17 ratio 1.8-
2.2), [20] additional cells should be recounted or scoring should be performed in an 
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alternative area of tissue. However, they also concluded that silver in situ hybridization is a 
more suitable methodology than fluorescence in situ hybridization for assessing HER2 status 
in gastric tumor samples as it is a bright-field methodology and thus allows for rapid 
identification of HER2-positive tumor foci within a heterogeneous sample.  
Comparing FISH and SISH methods for HER2 test in gastric cancer was also reported by 
several studies. Park et al [41] (2012) compared both SISH and FISH HER2 tests in Korea 
gastric adenocarcinoma 588 cases. They found only 9 cases with discrepancy, yielding a 
98.3% concordance rate. Garcia-Garcia et al [46] (2011) compared both SISH and FISH HER2 
tests in Spanish gastric adenocarcinoma in 166 cases. They found 96% concordance rate. 
Long et al [47] (2011) compared both SISH and FISH HER2 tests in China gastric 
adenocarcinoma 80 cases. They found only one case with discrepancy, yielding a 99% 
concordance rate. From above studies, FISH and SISH showed similar positive rates. The 
only difference between two methods is that SISH is much easier to count the HER2 signals.  
HER2 amplification or overexpression in primary tumor vs metastatic tumor was also 
reported. Bozzetti  et al [48] (2011) tested HER2 status with both FISH and IHC. The found 
that concordance of HER2 status between primary and metastatic tumor is 98.2% by FISH 
and 94.9% by IHC. They concluded that HER2 status is maintained in most cases unchanged 
during the metastatic process.  
HER2 amplification or overexpression correlating with patient survival and 
clinicopathological features: In breast cancer, HER2 amplification or overexpression is 
clearly associated with poorer prognosis and aggressive disease. However, the prognosis of 
HER2 amplification or overexpression in gastric cancer is controversial. In addition, the 
association of HER2 positive gastric cancer with clinicopathological features are also not 
consistent. 
Yonemura  et al [49] (1991) first reported HER2 overexpression in 260 primary gastric 
cancer. Patients with erbB-2 protein-positive tumors had 5-fold greater relative risk of death, 
as compared with those with erbB-2 protein-negative tumors. erbB-2 protein expression was 
associated with serosal invasion, lymph node metastasis, and lymphatic invasion.  Later, 
their results were confirmed by Nakajima et al (1999). Nakajima et al. [50](1999) also 
reported HER2 overexpression in 16.4% of gastric cancer, which was associated with 
significantly poorer survival. However, Kim et al. [51] (1994) studied the HER2 
overexpression in 152 Korea gastric carcinoma patients. They reported that the survival 
analysis of 104 patients with stage III gastric carcinoma revealed no significant association 
between c-erbB-2 staining status and survival duration. The 5-year survival rates of the c-
erbB-2 positive group and its negative group were 21% and 28%, respectively. In addition, 
there was little association between staining of c-erbB-2 protein and clinicopathological 
findings such as age, sex, location, histology, gross type, lymph node status, depth of 
invasion, and stage. However, other Korea studies found HER2 positive gastric cancer had a 
poor prognosis [41,52]. Park et al [41] reported that HER-2/neu overexpression and 
amplification in 182 gastric cancer Korea patients was examined with IHC. Twenty-nine  of 
182 patients expressed the HER-2/neu protein by IHC. Tumors with HER-2/neu 
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amplification were associated with poor mean survival rates (922 vs 3243 days) and 5-year 
survival rates (21.4% vs 63.0%; P < 0.05). Age, TNM stage, and amplification of HER-2/neu 
were found to be independently related to survival by multivariate analysis. In another 
Korea study with 1,414 cases and 595 tissue microarray cases, HER2-positivity was detected 
in 12.3% of whole-tissue sections and 17% of TMAs [53]. They found that HER2-positivity 
was correlated with age, histological type, lymphovascular invasion, and lymph node 
metastasis. Multivariate analyses of the differentiated gastric carcinoma subgroup revealed 
that HER2-positivity was an independent poor prognostic.  
Zhang et al (2009) studied the HER2 and HER3 overexpression in Chinese gastric cancer 
with 102 cases.  Overexpression of HER2 and HER3 was detected around 18.6% and 13.7%. 
HER2 and HER3 overexpression was correlated with a significantly worse survival (p = 
0.046 and 0.024, respectively). The overexpression rates of HER2 and HER3 in phase III-IV 
(TNM stage) disease were significantly higher than that in phase I-II disease (24.0% vs. 7.7%, 
p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively). They proposed that HER3 may become 
another molecular target.  
In European and United States, Tanner  et al [54] (2005) found that HER2 amplification was 
present in 12.2% of the 131 gastric cancer and 24% of the 100 GEJ adenocarcinomas in 
Finland which was associated with poor carcinoma-specific survival.  In contrast, Kunz 
[55](2012) reported that twelve of 99 (12%) gastric carcinomas were positive for HER2 and 
seven of 70 (10%) gastroesophageal junction carcinomas were positive for HER2. HER2 
status or primary tumor site did not correlate with patient survival. 
Recently, Jorgensen and Hersom [56]  (2012) reviewed previous studies with more than 100 
patients and analysis of association between the HER2 status and survival or relevant 
clinicopathological characteristics. Forty-two publications with a total of 12,749 patients 
fulfilled the two criteria and were reviewed in detail. The majority of the publications (71%) 
showed that a HER2-postive status measured either by IHC or ISH was associated with 
poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph 
node metastases, disease stage, or distant metastases. Based on the current analysis a clear 
trend towards a potential role for HER2 as a negative prognostics factor in gastric cancer 
was shown, suggesting that HER2 overexpression and/or amplification is a molecular 
abnormality that might be linked to the development of gastric cancer  
Trastuzumab or other HER2 related medication on treatment of HER2 amplification 
gastric adenocarcinoma: Trastuzumab, a monoclonal antibody that targets HER2, induces 
antibody-dependent cellular cytotoxicity, inhibits HER2-mediated signaling, and prevents 
cleavage of the extracellular domain of HER2[12]. Trastuzumab were found to inhibit tumor 
growth in gastric carcinoma cell lines, animal model and xenograft models[23, 33, 57, 58]. 
Fujimoto-Ouchi (2007) used trastuzumab as a single agent inhibited the tumor growth in 
both of the HER2-overexpressing models but not in the HER2-negative models, GXF97 and 
MKN-45. In any combination with capecitabine, cisplatin, irinotecan, docetaxel, or 
paclitaxel, trastuzumab showed more potent antitumor activity than the anticancer agents 
alone. A three-drug combination of capecitabine, cisplatin, and trastuzumab showed 
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remarkable tumor growth inhibition. Since breast cancer showed better prognosis with 
trastuzumab treatment for HER2 positive breast cancer patients, clinical trial was also 
performed in gastric carcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, 
international, phase 3, randomised controlled trial undertaken in 122 centers in 24 
countries[22]. Patients with gastric or gastro-esophageal junction cancer were eligible for 
inclusion if their tumors showed overexpression of HER2 protein by immunohistochemistry 
or gene amplification by fluorescence in-situ hybridization. Participants were randomly 
assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus 
cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in 
combination with intravenous trastuzumab. 594 patients were randomly assigned to study 
treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296). Median 
follow-up was 18·6 months in the trastuzumab plus chemotherapy group and 17·1 months 
in the chemotherapy alone group. Median overall survival was 13·8 months in those 
assigned to trastuzumab plus chemotherapy compared with 11·1 months in those assigned 
to chemotherapy alone (hazard ratio 0·74). 
Although the survival improvement about 3 months, it is a great breakthrough for gastric 
carcinoma treatment since the survival of these cancer has not change for a decade. After 
ToGA clinical trial, trastuzumab combined with standard chemical therapy (such as 
capecitabine or 5-fluorouracil and cisplatin) now is approved by European Medicines 
Agency, United States and Japan etc. for the treatment of patients with HER2 
overexpression or amplification. In addition, laptinib showed a synergistic effect with 
trastuzumab in vitro and in vivo to inhibit HER2 amplified human gastric cancer cells and 
animal model [23]. Clinical phase II trial of lapatinib as first line therapy in patients with 
advanced or metastatic cancer showed well tolerated, which will be another potential drug 
to target HER2 receptors[59]. 
3. HER2 in esophageal adenocarcinoma 
EAC incidence has increased 6 folds in United States and Western countries in the last three 
decades and the prognosis is usually very poor with 5-year survival rates ranging from 14-
22%[60-63]. While surgical treatment of EAC can offer cure, many patients first present as a 
disseminated disease and require systemic therapy. Current chemotherapy regimens 
provide only minimal survival benefit, predominantly when used in combination with 
surgery or radiation. Recently clinical trial (ToGA) in Asian and European countries showed 
that anti-HER2 monoclonal antibody trastuzumab treatment significantly improved the 
survival of patients with gastric adenocarcinoma and HER2 overexpression and 
amplification. The clinical trial of trastuzumab to treat esophageal adenocarcinoma patients 
are approved in United States and European countries. Here is a comprehensive review of 
HER2 overexpression and amplification in esophageal adenocarcinoma.  
IHC studies on HER2 overexpression: In esophageal adenocarcinoma, HER2 
overexpression and amplification recently has been reported at frequencies similar to those 
observed in breast cancer. Based on most reports from English literature, the frequency of 
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HER-2 immunohistochemistry shows an average of 12%. The current problems for IHC test 
for HER2 overexpression is the standard score criteria of the intensity of IHC stain. Recently, 
Zhou and his colleagues (2011) set up a new score criteria which is modified from 
Hoffman’s gastric adenocarcinoma score system (Table 3). In our modified score criteria, 
IHC 2+ will be counted as positive HER2 overexpression since all IHC 2+ case had HER2 
amplification with CISH test. However, the recent Mayo Clinic study reported that only 15% 
of IHC2+ cases showed HER2 amplification with FISH tests with breast HER2 criteria. It is 
difficult to compare their criteria since there are no pictures in their reports.            
FISH and CISH studies on HER2 amplification: In esophageal adenocarcinoma, HER2 
amplification recently has been extensively studies. Reichelt et al. found that 15% (16/110) of 
tumors had HER2 gene amplification with FISH. Similarly, Brien et al. showed that 19% 
(12/63) of esophageal adenocarcinomas had HER2 gene amplification. In addition, with 3-
dimentional FISH method in thick slides (16 µm, n=124), Rauser et al. [64] found that HER2 
amplification was 10.5% in high-level amplification (≥ 6.0 signals) and 60% in low-level copy 
number change ( ≥ 2.5-4.0 signals). However, in thin slides (4 µm, n=123), HER2 
amplification was found in 9 % in high-level amplification (≥ 6.0 signals) and 6 % in low-
level copy number change ( ≥ 2.5-4.0 signals). However, there is a huge difference between 
traditional FISH in thin section (6%) and three-dimensional FISH in thick section (60%) to 
detect the low-level HER2 amplification. They considered that the tumor cell nuclei were 
truncated due to standardized thin tissue sectioning. Therefore, three dimension FISH need 
to be further evaluated to help better understand any prognostic significance. In our study, 
we found that HER2 amplification was 18% (21/116) detected by CISH and 16.4% (19/116) by 
high definition microarray in cases of esophageal adenocarcinoma. In addition we found no 
evidence of HER2 amplification in low grad dysplasia, Barrett’s esophagus, columnar cell 
metaplasia or normal esophageal squamous epithelium. Thus, the frequency of HER2 
amplification in esophageal adenocarcinoma appears to be consistent between studies with 
a range of 15-19% and this event appears not to occur prior to the development of high 
grade dysplasia.  Radu et al65 (2012) compared HER2 antibodies with FISH tests. They used 
CAP definition of HER2 amplification to evaluate the FISH results. They found that the very 
high HER2 amplification rate (30/103, 29%) with HER2/CEP17 ≥ 2.2 and (32/102, 31%) with 
HER2/CEP17 ≥ 2.0. From their slides, they used 5 µm instead of 3-4 µm routine section. 
Actually the similar phenomenon was reported in esophageal adenocarcinoma cases 64. 
Using 16 µm vs 4 µm sections for HER2 FISH tests, they found that 16 µm sections showed 
higher HER2 amplification than 4 µm. Higher HER2 amplification from Radu may be 
caused by thicker section. 
HER2 amplification or overexpression correlating with patient survival and 
clinicopathological factors: In esophageal adenocarcinoma, the relationship between HER2 
amplification and prognosis is limited and controversial [66, 67]. Brien et al. [66] found that 
patients with HER2 amplification (n=11) had shorter survival durations than did patients 
without amplification (n=43). In contrast, Reichelt et al.67 found no survival difference 
between the HER2 amplification (n=16) and no HER2 amplification groups (n=90)(p=0.953). 
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In addition,  Rauser et al.28 found that HER2 gene amplification was associated with 
increased disease-specific mortality on 3-dimensional fluorescence in situ hybridization 
(FISH) analysis in thick slides (16 µm), but not on FISH and immunohistochemical analyses 
in thin (4 µm) sections. Our results 68 indicate no association of HER2 amplification with 
patient survival in a large cohort studies (total 232 patients) by both CISH and high density 
DNA microarrays methods although HER2 amplification group shows better prognosis (23 
months vs 25 months). However, Yoon et al69 (2012) found that HER2 amplification 
significantly associated with improved overall survival (n=713) with 35% of HER2 positive 
patients alive at 5 years as compared with 26% of HER2 negative patients. It is interesting 
that they divided the HER2 positive EAC into two groups: EAC with and without adjacent 
BE. They found that HER2 positive EAC with BE significantly associated with disease 
specific survival and overall survival, but HER2 positive EAC without BE was not 
significantly associated with disease-specific-survival and overall survival. The prognosis of 
HER2 positive EAC patients still cannot be concluded. At present, we can say HER2 positive 
EAC patients do not show worse prognosis.  
The association between HER2 amplification and these clinicopathological factors were 
controversial. First, Brien [66] 2000 reported that HER2 amplification was not significantly 
associated with any clinicopathological features such as depth of tumor invasion, lymph 
node metastasis, differentiation and pathological stage. Reichelt et al [67]  (2007) found that 
HER2 amplification was not associated with pathological staging (TNM) and grade. In our 
study [68], 21 of 116 EAC patients had HER2 amplification. Nineteen were male, and 2 
female (M:F ratio, 10:1), with a mean age of 63 years (range, 51 to 74 years). The remaining 
patients (85 males and 10 females [M:F ratio, 9:1]; mean age, 65 years [34 to 85 years]) had no 
amplification. A Fisher’s exact test shows that there is no significant association between 
HER2 and gender (p=1.0), age (p =0.188,), the stage (p =0.325), and the number of metastatic 
lymph nodes (p =0.234). However, the frequency of HER2 amplification was found to be 
significantly higher (p=0.004) in moderately differentiated tumors (13/22) compared with 
poor or well differentiated tumors (1/6 and 7/61 respectively). Yoon [69](2012) study 
supported our finding that HER2 amplification cases were significantly associated with 
better differentiation, but HER2 amplification cases were not associated with age and 
gender. However, they also showed that HER2 amplification was associated with lower 
depth of tumor invasion (T stage), fewer malignant nodes, and absence of signet ring cells.  
In summary, the association of HER2 amplification with survival and clinicopathological 
features is not very clear. At least HER2 amplification was not associated with worse 
prognosis in most large cohort studies. In addition, the HER2 amplification may be 
associated better differentiation, but not associated with age and sex. The large, multi-
institute study is needed to confirm current studies.  
Trastuzumab or other HER2 related medication on treatment of HER2 amplification 
esophageal adenocarcinoma: Safran et al [70, 71] (2004, 2007) first reported clinical trial with 
trastuzumab, paclitaxel, cisplatin and radiation for locally advanced esophageal 
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adenocarcinoma patients with HER2 overexpression. They took patients with histologically 
documented EAC with T3, T4 or lymph nodal disease. They used IHC 2+ and 3+ with more 
than 10% cells as HER2 positive overexpression and set FISH ratio greater than 2 as HER2 
amplification. The median survival for all 19 patients is 24 months, which is similar to prior 
studies. Esophagitis, nausea, dehydration, and neutropenia were the most common toxicity. 
However, toxicity was modest with only 2 patients (10%) having grade 3-4 esophagitis. 
Therefore, trastuzumab does not increase toxicities when added to chemoradiation for 
patients with esophageal cancer.  
ToGA clinical trials in patients with gastric adenocarcinoma (trial vs control: 236 vs 243 
patients) and gastroesophageal junction adenocarcinoma (trial vs control: 58 vs 48 patients) 
have shown a significant survival benefit for patients treated with a combination of 
trastuzumab and standard chemotherapy.[22,72] Now Safran and colleagues started Phase 
III clinical trial to study Radiotherapy, Paclitaxel, and Carboplatin with versus without 
Trastuzumab in patients with HER2-overexpressing esophageal adenocarcinoma (RTOG-
1010, and NCI web site: http://www.cancer.gov/ncicancerbulletin/062811/page6). Their 
primary goal is to determine whether trastuzumab increases disease-free survival when 
combined with radiotherapy, paclitaxel, and carboplatin followed by surgery in patients 
with HER2-overexpressing esophageal adenocarcinoma. It is interesting to follow up their 
results. 
4. HER2 in breast cancers 
Among new breast cancer patients, 15% to 20% will develop tumors that harbor a genomic 
alteration involving the HER2 gene locus. This alteration results in amplification of an 
amplicon on chromosome 17 that contains the HER2 proto-oncogene[73, 74]. Gene 
amplification is the primary mechanism that drives HER2 receptor protein over-expression 
in this important subset of breast cancers. HER2 over-expression resulting from gene 
amplification dramatically increases the likelihood of receptor activation and signaling, 
contributing to a more aggressive tumor biology and is associated with worse clinical 
outcome including higher rates of early, predominantly visceral and central nervous system 
recurrence and mortality. [75, 76]  In addition to the prognostic impact, HER2 over-
expression in breast cancer is highly correlated with a younger age at presentation, higher 
tumor grade as well as a higher tumor burden compared with HER2 negative disease [77]. 
HER2 over-expression in breast cancer was recognized early on as being an ideal target for 
therapy, given the location of the receptor on the surface of tumor cells and its role in 
driving the clinical course of disease for the subset of patients with the HER2 alteration [78], 
[79]. The drug Trastuzumab was developed as a targeted biologic therapeutic against the 
HER2 receptor protein. Trastuzumab is a humanized monoclonal antibody that combines 
the mouse recognition sequence of a monoclonal antibody (clone 4D5) against an 
extracellular epitope of the receptors with a human IgG1[74]. Trastuzumab demonstrates a 
high affinity and specificity for the HER2 receptor and in preclinical studies was shown to 
be effective at inhibiting the growth of HER2 over-expressing breast cancer cells.[80] 
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In numerous clinical trials, targeting HER2 has been shown to be remarkably effective 
against HER2 positive breast cancer in both the metastatic and the adjuvant settings, 
particularly in combination with cytotoxic chemotherapy. Treatment with the drug 
Trastuzumab has been shown to improve response rates, time to progression, and even 
survival when used alone[18] or added to chemotherapy in metastatic setting .[78] The 
success of therapeutically targeting HER2 in the metastatic setting led to several 
international, prospective randomized trials that have demonstrated that adjuvant 
trastuzumab reduces the relative risk of recurrence by half and mortality by one third in 
early-stage breast cancer.[81-84] The data from these clinical trials highlights the importance 
of accurate HER2 testing for every newly diagnosed breast cancer patient in order to help 
select those patients who will be the most suitable candidates for HER2 targeted therapy. 
[85] 
Clinical assays to assess the HER2 status include IHC, which detects protein over-
expression, or FISH, which detects gene amplification. [85-87] Both assays have been 
clinically validated in the above mentioned prospective randomized clinical trials and have 
received FDA approval for predicting a clinical response and patient benefit from HER2-
targeted treatment. Published data from these clinical trials suggest that only those patients 
whose breast cancer demonstrates protein over-expression and/or gene amplification by the 
above assays are likely to benefit from therapy with Trastuzumab. [88] Since the results of 
HER2 assays stand alone in determining which breast cancer patients will be the most 
appropriate for HER2-targeted therapy, accurate, reliable and reproducible results are a 
high priority for ensuring optimal patient treatment. 
The ASCO/CAP task force, has published recommendations for HER2 testing, in which the 
panel has concluded that both tests were equally efficient in identifying patients who are 
candidates for HER2-targeted therapy, as long as the assays have been properly validated 
and all aspects of the testing is performed in a highly standardized fashion with a rigorous 
quality assurance program. [89] This task force also recognized the importance of 
standardizing pre-analytical variables including tissue handling and fixation to improve the 
quality of clinical samples for predictive factor analysis. [90] The IHC and FISH 
methodologies for evaluating the HER2 status in breast cancer are complementary in nature. 
[91] These tests examine different aspects of the biology that underlies HER2 driven breast 
tumors. FISH evaluates the status of the HER2 gene in the nucleus and is a surrogate for 
protein expression, while IHC directly evaluates over-expression of the receptor protein at 
the surface of the cell. In the majority of HER2-positive cancers, HER2 protein over-
expression is the result of gene amplification, thus HER2 gene/protein status should be 
highly correlated in most cases. Consequently, HER2 gene/protein discordant results in the 
majority of cases are related to technical issues. However, unusual HER2 genotypes such as 
polysomy for chromosome 17 and genomic heterogeneity can lead to discrepant non-
correlating cases that may be clinically important. [92, 93] For such cases, the assessment of 
both the gene and the protein may be necessary in order to sort out the most appropriate 
HER2 status for the purpose of determining therapy.  
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Despite the remarkable clinical efficacy of HER2 targeted therapy, not all patients respond 
and de novo as well as acquired resistance remains an important clinical issue.  Currently 
there are no clinically validated factors that can be used to predict resistance to HER2 
targeted therapy in breast cancer.  Preclinical data and more recent clinical studies have 
suggested a number of potential mechanisms of resistance including reduction of antibody 
affinity and binding due to steric hindrance from MUC4 over-expression, constitutively 
active downstream signaling involving p27 Kip1, PTEN, PI3K, mTOR, and Akt as well as 
cross-talk with other signaling pathways including EGFR and IGFR-1, that can by-pass 







Age  63 (51-74)  65 (34-85)  0.188 
       
Gender  MALE FEMALE MALE FEMALE 1.0 
  19 2 85 10  
       
  POS NEG POS NEG  
Lymph node 
METASTASIS 
 13 8 69 26 0.234 
       
pStaging      0.325 
 I 3  10   
 II 8  25   
 III 10  60   
       
Median survival
(months) 
 25 (7-71)  23 (0.03-108)  0.19 
Differentiation      0.004 
 poor 7  61   
 moderate 13  22   
 well 1  6   
Table 4. Association of HER2 amplified group and non-HER2 amplified group with multiple clinical 
factors (From Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria 
in esophageal adenocarcinoma. Mod Pathol 2011;24:899-907) 
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